


FORM PTO - 1449				ATTORNEY DOCKET NO.: UPA-008					
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT				APPLICANT: Whitehead					
				SERIAL NO.: 10/045,360					
				FILING DATE: January 22, 2002					
				GROUP: Not yet assigned					
U.S. PATENT DOCUMENTS									
EXAM. INIT.		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE		
FOREIGN PATENT DOCUMENTS									
EXAM. INIT.		DOCUMENT NUMBER	DATE	COUNTRY CODE	CLASS	SUB CLASS	FILING DATE	ABSTRACT ONLY	ENGLISH LANG (Y/N)
OTHER ART, JOURNAL ARTICLES, ETC.									
EXAM. INIT.	OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)								
2	C30	Baumann et al., "Interaction of Cytokine- and Glucocorticoid-Response Elements of Acute-Phase Plasma Protein Genes", The Journal of Biological Chemistry, Vol. 265, No. 36, pp. 22275-22281, December 25, 1990.							
1	C31	Nickerson et al., "Automated DNA Diagnostics Using an ELISA-Based Oligonucleotide Ligation Assay", Proc. Natl. Acad. Sci., Vol. 87, pp. 8923-8927, November 1990.							
↓	C32	Scheidereit et al., "The glucocorticoid Receptor Binds to Defined Nucleotide Sequences Near the Promoter of Mouse Mammary Tumour Virus", Nature, Vol. 304, pp. 749-752, August 25, 1983.							
2	C33	Tobe et al., "Single-Well Genotyping of Diallelic Sequence Variations by a Two-Color ELISA-Based Oligonucleotide Ligation Assay", Nucleic Acids Research, Vol. 24, No. 19, 1996.							
EXAMINER				DATE CONSIDERED					
				12/96					



FORM PTO - 1449 INFORMATION DISCLOSURE STATEMENT	EXPRESS MAIL MAILING LABEL NO.: EL953456281US ATTORNEY DOCKET NO.: UPA-008 APPLICANT: Whitehead SERIAL NO.: 10/045,360 FILING DATE: January 22, 2002 GROUP: Not yet assigned
---	---

U.S. PATENT DOCUMENTS

EXAM. INIT.	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS



EXAM. INIT.	DOCUMENT NUMBER	DATE	COUNTRY CODE	CLASS	SUB CLASS	FILING DATE	ABSTRACT ONLY	ENGLISH LANG (Y/N)

OTHER ART, JOURNAL ARTICLES, ETC.

EXAM. INIT.	OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)
✓	C1 Butler et al., "Structure of the Mouse Serum Amyloid A 5 (SAA5) Gene: Relationship to Other Members of the Serum Amyloid A Family", Scand. J. Immunol., Vol. 45, pp. 160-165, 1997.
	C2 Butler et al., "Mapping of the Mouse Serum Amyloid A Gene Cluster by Long-Range Polymerase Chain Reaction", Immunogenetics, Vol. 44, pp. 468-474, 1996.
	C3 Cohen et al., "Therapy of Relapsing Multiple Sclerosis. Treatment Approaches for Nonresponders", J. Neuroimmunol., Vol. 98, pp. 29-36, 1999.
	C4 Cunnane et al., "Amyloid Precursors and Amyloidosis in Rheumatoid Arthritis", Bailliére's Clinical Rheumatol., Vol. 13, No. 4, pp. 615-628, 1999.
	C5 Cunnane et al., "Serum Amyloid A in the Assessment of Early Inflammatory Arthritis", Rheumatol., 27:1, 2000.
	C6 Gaughan et al., "Ribozyme Mediated Cleavage of Acute Phase Serum Amyloid A (A-SAA) mRNA in Vitro", FEBS Letters, 374, pp. 241-245, 1995.
	C7 Gaughan et al., "Efficient In Vitro Cleavage of Mouse Acute Phase Serum Amyloid A mRNA Mediated by a Synthetic Hammerhead Ribozyme", Scand. J. Immunol., Vol. 46, pp. 51-58, 1997.
✓	C8 Grehan et al., "Expression of a Biologically Active Recombinant Mouse IL-1 Receptor Antagonist and its Use in Vivo to Modulate Aspects of the Acute Phase Response", J. Immunol., pp. 369-378, 1997.
✓	C9 Grehan et al., "Down-Regulation of the Major Circulating Precursors of Proteins Deposited in Secondary Amyloidosis by a Recombinant Mouse Interleukin-1 Receptor Antagonist", Eur. J. Immunol., Vol. 27, pp. 2593-2599, 1997.



FORM PTO - 1449 INFORMATION DISCLOSURE STATEMENT		ATTORNEY DOCKET NO.: UPA-008 APPLICANT: Whitehead SERIAL NO.: 10/045,360 FILING DATE: January 22, 2002 GROUP: Not yet assigned
1	C10	Hanauer et al., "Management of Crohn's Disease in Adults", Amer. J. Gastroenter., Vol. 92, No. 4, 1997.
	C11	Hendrickse et al., "Rifampicin-Induced Non-Responsiveness to Corticosteroid Treatment in Nephrotic Syndrome", Brit. Med. J., p. 306, February 3, 1979.
	C12	Jain et al., "Rifampicin Induced Non-Responsiveness to Steroids in Bronchial Asthma", Indian. J. Chest. Dis. & All Sci., Vol. 31, No. 4, pp. 271-274, 1989.
	C13	Jensen et al., "Competitive Reverse Transcription Polymerase Chain Reaction for Quantifying Pre-mRNA and mRNA of Major Acute Phase Proteins", J. Immunol. Meth., Vol. 215, pp. 45-48, 1998.
	C14	Jensen et al., "Review Article - Regulation of Serum Amyloid A Protein Expression During the Acute-Phase Response", Biochem. J., Vol. 334, pp. 489-503, 1998.
	C15	Jensen et al., "Evolutionary Analyses and Acute Phase Response", J. Immunol., pp. 384-392, 1997.
	C16	Jorgensen et al., "Serum Amyloid A Transcription in Atlantic Salmon (<i>Salmo salar</i> L.) Hepatocytes is enhanced by Stimulation with Macrophage Factors, Recombinant Human IL-18, IL-6 and TNF α or bacterial lipopolysaccharide", Devel. and Compar. Immunol., Vol. 24, pp. 553-563, 2000.
	C17	Kornbluth et al., "Ulcerative Colitis Practice Guidelines in Adults", Am. J. of Gastroent., Vol. 92, No. 2, 1997.
	C18	Longley et al., "Posttranscriptional Regulation of Acute Phase Serum Amyloid A2 Expression by the 5'- and 3' - Untranslated Regions of Its mRNA", J. Immunol., pp. 4538-4545, 1999.
	C19	McCormack et al., "Generation of Soluble Recombinant Human Acute Phase Serum Amyloid A2 (A-SAA2) Protein and its Use in Development of a A-SAA Specific ELISA", J. Immunol. Meth., Vol. 198, pp. 101-110, 1996.
	C20	O'Hara et al., "Acute-Phase Serum Amyloid A Production by Rheumatoid Arthritis Synovial Tissue", Arthritis Res. Vol. 2, pp. 142-144, 2000.
	C21	O'Mahony et al., "Review Article: Management of Patients with Non-Responsive Coeliac Disease", Aliment Pharmacol. Ther., Vol. 10, pp. 671-68, 1996.
	C22	Present, "How To Do Without Steroids in Inflammatory Bowel Disease", Inflamm. Bowel Dis., Vol. 6, No. 1, February 2000.
	C23	Rebuck, "Asthma: Non-Responsiveness to Conventional Therapy", Eur. J. Respir. Dis., 69 (Suppl. 147), pp. 105-109, 1986.
	C24	Rygg et al., "In Vitro Evaluation of an Enhanced Human Serum Amyloid A (SAA2) Promoter-Regulated Soluble TNF Receptor Fusion Protein for Anti-Inflammatory Gene Therapy", Scand. J. Immunol., Vol. 53, pp. 588-595, 2001.
2	C25	Spitz et al., "Response to the Antiprogesterone RU 486 (mifepristone) During Early Pregnancy and the Menstrual Cycle in Women", J. Reprod. Fert., Suppl., Vol. 37, pp. 253-260, 1989.

FORM PTO - 1449 INFORMATION DISCLOSURE STATEMENT				ATTORNEY DOCKET NO.: UPA-008 APPLICANT: Whitehead SERIAL NO.: 10/045,360 FILING DATE: January 22, 2002 GROUP: Not yet assigned	
1	C26	Steel et al., "Expression and Regulation of Constitutive and Acute Phase Serum Amyloid A mRNAs in Hepatic and Non-Hepatic Cell Lines", Scand. J. Immunol., Vol. 44, pp. 493-500, 1996.			
	C27	Uhlar et al., "Wallaby Serum Amyloid A Protein: cDNA Cloning, Sequence and Evolutionary Analysis", Scand. J. Immunol., Vol. 43, pp. 271-276, 1996.			
	C28	Uhlar et al., "The Kinetics and Magnitude of the Synergistic Activation of the Serum Amyloid A Promoter by IL-1 β and IL-6 is Determined by the Order of Cytokine Addition", Scand. J. Immunol., Vol. 49, pp. 399-404, 1999.			
4	C29	Uhlar et al., "Use of the Acute Phase Serum Amyloid A2 (SAA2) Gene Promoter in the Analysis of Pro- and Anti-Inflammatory Mediators: Differential Kinetics of SAA2 Promoter Induction by IL-1 β and TNF- α compared to IL-6", J. Immunol. Meth., Vol. 203, pp. 123-130, 1997.			
2	C30	Uhlar et al., "Review Article - Serum Amyloid A, the Major Vertebrate Acute-Phase Reactant", Eur. J. Biochem., Vol. 265, pp. 501-523, 1999.			
EXAMINER 		DATE CONSIDERED 12/8/01			

2298727